Last updated: February 17, 2026
What Is the Current Market Position of NDC 69681-0125?
The drug with NDC 69681-0125 is Kynamro (mipomersen). It is approved by the FDA for the treatment of homozygous familial hypercholesterolemia (HoFH), a genetic condition characterized by extremely high LDL cholesterol levels resistant to standard therapies.
Kynamro was first approved in 2013. As a second-line therapy, its market uptake has been limited relative to more established lipid-lowering agents. Its primary sales are concentrated within niche patient populations due to high cost, limited administration routes, and safety concerns.
How Has the Market for Kynamro Evolved?
Market Size and Demand
- The global homozygous familial hypercholesterolemia (HoFH) population is estimated at approximately 1,300 to 2,000 patients in the U.S. (per 2020 estimates), with higher figures globally.
- U.S. prescriptions for mipomersen have remained low, with less than 100 annual prescribers and fewer than 1,000 annual prescriptions in recent years, reflecting limited market penetration.
- The drug's sales peaked at approximately $33 million in 2014. Since then, sales have declined due to safety concerns and competition from newer therapies.
Competitive Landscape
- PCSK9 inhibitors (evolocumab, alirocumab) entered the market after 2015, heavily penetrating the HoFH population and offering more convenient administration.
- Lomitapide also competes, with oral administration but limited by liver toxicity risk.
- The emergence of gene therapies (e.g., AMG 890) poses long-term competition, although these are in clinical trials.
Regulatory and Reimbursement Environment
- Uptake is limited by high drug costs (~$165,000 annually in the U.S.), which are partially offset by insurance reimbursement but still discourage many prescribers.
- The FDA's black box warning for hepatotoxicity impacts prescribing confidence and patient willingness to undergo treatment.
Price Projections for NDC 69681-0125
Historical Price Trends
- Wholesale Acquisition Cost (WAC) stood at approximately $165,000 per year in recent years.
- Actual reimbursement rates are lower due to discounts, rebates, and negotiated prices with insurers.
Future Price Trends
- No significant price reductions are projected in the near term. Price erosion for niche drugs like mipomersen is limited, given the small patient population and high development costs.
- Larger manufacturers in the specialty drug segment have maintained or slightly increased prices, citing high R&D costs and limited competition.
Market-Driven Price Outlook
| Year |
Price Estimate (WAC) |
Notes |
| 2023 |
~$165,000 |
Stable, barring policy changes or new competitors |
| 2024 |
~$165,000 |
No major price reduction anticipated |
| 2025 |
~$165,000 |
Market dynamics unlikely to induce significant change |
Potential Factors Influencing Future Market and Pricing
- Emerging gene therapies targeting HoFH could render mipomersen obsolete, reducing demand and pressuring prices downward.
- Regulatory changes aimed at controlling high drug costs may influence pricing strategies.
- Safety concerns might limit prescriber confidence, impacting demand stability.
Key Market Considerations
- Limited patient population constrains scalable revenue.
- Reimbursement challenges restrict profitability.
- Competing therapies with broader indications and easier administration diminish mipomersen’s market share.
- Patent status is active, with no imminent patent expirations.
Summary
NDC 69681-0125 (Kynamro) operates in a niche market with small patient numbers. Sales peaked in 2014 and have declined since. The drug’s prescribing remains limited, with annual revenue around $30-$35 million and stable pricing near $165,000 WAC. The outlook suggests negligible price reductions unless market dynamics shift significantly, such as the advent of gene therapies or policy reforms.
Key Takeaways
- The market for mipomersen is constrained by small patient numbers and competition from convenient, effective alternatives like PCSK9 inhibitors.
- Current pricing remains stable, with limited prospects for significant reductions.
- Future demand hinges on new therapies and regulatory policies addressing drug costs.
- The drug's niche status and safety profile limit broader adoption.
- Long-term growth prospects are minimal absent major therapeutic advances or market expansions.
FAQs
Q1: What are the primary competitors to NDC 69681-0125?
PCSK9 inhibitors (evolocumab, alirocumab) and lomitapide.
Q2: Is there potential for price increases in the near future?
No, pricing stability is expected barring policy shifts or market disruptions.
Q3: How many patients are estimated to use mipomersen in the U.S.?
Less than 2,000 patients, with actual prescriptions under 1,000 annually.
Q4: What factors could reduce the drug’s market share?
Emergence of gene therapies, safety concerns, and coverage limitations.
Q5: Will new treatments affect mipomersen’s sales significantly?
Yes, gene therapies and newer lipid-lowering agents could displace mipomersen, further shrinking its market.
References
- U.S. FDA. Kynamro (mipomersen) prescribing information, 2013.
- IQVIA. Pharmaceutical Market Data, 2022.
- EvaluatePharma. Global sales estimates, 2022.
- Centers for Disease Control and Prevention. FH prevalence data, 2020.
- Industry reports on HoFH therapeutic landscape, 2022.
